MMRGlobal Biotech Assets in Play as Company Is Awarded Second U.S. Cancer Fighting Patent

LOS ANGELES, CA--(Marketwired - Feb 2, 2015) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic document management and imaging systems for healthcare professionals, today announced that U.S. Patent No. 8,945,550 will issue on February 3, 2015, providing the second U.S. patent, in addition to patents in Australia, Mexico and South Korea, for the Company's anti-CD20 monoclonal antibody technology. MMR also announced that it is in talks to sell more than 2,000 patient samples and data from its FavId™ vaccine trials to treat lymphoma patients with two major biotech companies that could use the samples for research and development or in connection with drug approval. This second MMR U.S. biotech patent relates to methods of treatment using the anti-CD20 monoclonal antibodies and will be issued under the title, "Antibodies and Methods For Making and Using Them."

The Company has continued to enforce MMR's IP and monetize it by entering into license agreements which have already generated millions of dollars in revenue to the Company. Global interest in monoclonal antibodies such as MMR's anti-CD20 antibodies in cancer research and other areas of medicine is also intensifying as evidenced by research at the National Cancer Institute, Mayo Clinic, MD Anderson & numerous others (http://www.mdanderson.org/education-and-research/resources-for-professionals/scientific-resources/core-facilities-and-services/monoclonal-antibody-core-facility/index.html).

MMR's latest patent and patent application will provide additional protection of the Company's specific antibodies that have particular utility in fighting cancers. MMR's anti-CD20 monoclonal antibodies are important assets of the Company, the value and benefit of which are demonstrated by how these antibodies are used commercially in products like Rituxan®, the first anti-CD20 monoclonal antibody drug approved by the FDA with worldwide sales of $7.5 billion in 2013. The Company's anti-CD20 antibodies were developed to help provide low-cost alternatives for treatments like Rituxan® in connection with non-Hodgkin's lymphoma and other cancers widely considered too expensive for the world population of patients who need costlier forms of treatment to live.

As previously reported, the issuance of U.S. Patent No. 8,465,741 on June 18, 2013 provided the Company with its first U.S. patent for the anti-CD20 monoclonal antibodies. Thereafter, patents in Australia, Korea and Mexico were granted using various expedited examination techniques. This second U.S. patent granted is now the Company's fifth patent for its anti-CD20 monoclonal antibody technology and methods of using the same in treating cancers. Additional patent applications for the Company's antibodies remain pending in a number of other countries or regional authorities in addition to the U.S., including Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and Korea. The filings are part of the Company's plan to expand the scope of its biotech assets and other intellectual property.

MMRGlobal, through its wholly owned subsidiary, MyMedicalRecords, Inc., also owns numerous health information technology patents issued or pending related to providing online medical and Personal Health Records in 12 countries or regional authorities of commercial interest. These include the United States, where MMR has 13 issued patents and over 300 claims as well as additional applications and continuation applications, also with over 300 claims. The most recently issued U.S. patent, U.S. Patent No. 8,775,212, represents MMR's first Clinical Trials patent and includes 18 claims directed to methods and systems that provide for self-reporting being used to create Electronic Health Records for purposes including Clinical Trials. Foreign countries or regional authorities in which MyMedicalRecords, Inc. has health IT patents issued and/or pending include Australia, Singapore, New Zealand, Mexico, Canada, China, Hong Kong, Japan, South Korea, Israel, and Europe. MMR also has hundreds of claims either pending or published related to health IT worldwide.

In biotech, the Company had invested more than $100 million in research and development on its FavId™ vaccine trials and use of customized tumor cells to treat lymphoma patients and other technologies. MMR has continued to make progress in protecting the Company's IP, including its anti-CD20 antibodies and B-Cell vaccine patents entitled "Method and Composition for Altering a B-Cell Mediated Pathology," which relate to methods of manufacturing compositions for B-Cell vaccines used in the fight against lymphoma and potentially other forms of cancer. The biotech assets are part of a patent portfolio and other intellectual property the Company acquired through a reverse merger with San Diego-based biotechnology company Favrille, Inc. in 2009.

Although MMRGlobal will continue working to license and otherwise exploit an extensive portfolio of biotech assets, including its anti-CD20 monoclonal antibodies and data from vaccine trials, thousands of patient tumor samples and other intellectual property including numerous worldwide patents in various stages, it remains focused on its primary health IT business. 

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.

Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements are based on MMR's current assumptions, beliefs and expectations, and involve risks, uncertainties and other factors that may cause MMR's actual results to be materially different from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words such as "expect," "plan," "possibility," "offer," "if," "negotiate," "when," "believe," "will," "estimate," "continue," and similar expressions. Risks, uncertainties, and other factors that could cause or contribute to such differences include, but are not limited to: ongoing and future intellectual property enforcement actions; the ability to successfully litigate or settle claims of patent infringement; MMR's ability to develop, license and monetize its patent and the additional patents in the portfolio for both MMR's health IT and biotechnology IP assets; reliance upon the successful operations of its business partners in selling MMR's products and services, the timing of milestone payments in connection with licensing its IP; MMR's ability to obtain necessary financing, generate sufficient cash flow, and maintain appropriate indebtedness; and the increasing development of market competition in the area of personal and electronic health records. These factors and others are described in more detail in MMR's public filings with the Securities and Exchange Commission, including the risks discussed in the "Risk Factors" section in MMR's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of these reports can be found on MMR's website (www.mmrglobal.com) under the heading "Investor Relations." MMR is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.